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Objectives. We sought to determine whether brief, profound
inhibition of thrombin or prothrombin activation by factor Xa
limits neointimal formation and stenosis after arterial injury.
Background. Thrombin has been implicated as a mediator of
neointimal formation, but adjunctive administration of anticoag-
ulant agents has not proven effective to decrease restenosis in
patients undergoing coronary angioplasty.
Methods. We infused recombinant desulfatohirudin (r-hirudin,
bolus of 2 mg/kg body weight followed by 2 mg/kg per h, n  9),
heparin (100 U/kg per h, n 6) or recombinant tick anticoagulant
peptide (rTAP, 1-mg/kg bolus followed by 3 mg/kg per h, n  5),
a speciﬁc inhibitor of factor Xa, intravenously, beginning 15 min
before and for up to 3 h after repetitive balloon hyperinﬂations
sufﬁcient to disrupt the internal elastic lamina in a carotid artery
of minipigs with hypercholesterolemia induced by feeding them an
atherogenic diet.
Results. Partial thromboplastin time was increased six- to
sevenfold over baseline levels at the end of the infusions of the
anticoagulant agents. Lumen stenosis measured histologically 4
weeks after balloon-induced carotid injury was 29 16% (mean
SEM) in r-hirudin–treated, 52  19% in rTAP-treated and 76 
18% in heparin-treated pigs (p < 0.02 for r-hirudin vs. heparin
treatment).
Conclusions. The marked reduction of stenosis in r-hirudin–
treated animals indicates that thrombin plays a major role in
neointimal formation after balloon-induced arterial injury. A
relatively brief interval of profound, direct inhibition of thrombin
may be particularly effective to attenuate restenosis after balloon
angioplasty.
(J Am Coll Cardiol 1996;28:1849–55)
1996 by the American College of Cardiology
Balloon angioplasty of coronary arteries induces accelerated
restenosis (1–3). Thrombin has been implicated in this re-
sponse because it activates platelets and converts ﬁbrinogen to
ﬁbrin, forming thrombus (4,5), and because it serves as a
potent mitogen for vascular smooth muscle cells (6,7). How-
ever, conventional anticoagulation with heparin has failed to
attenuate restenosis in patients (8,9). More recent results in
experimental animals have shown decreased lumen stenosis
within 1 month when recombinant desulfatohirudin (r-
hirudin), a direct inhibitor of thrombin, was administered
during balloon or stent angioplasty (10,11). Nevertheless, in a
recent clinical study the investigators observed essentially no
effect on restenosis within 6 months when r-hirudin was
administered for up to 3 days after angioplasty (12). These
disparities may have resulted from species differences or from
incomplete local inhibition of thrombin, which activates factors
V, VIII and XI, thereby potentiating activation of coagulation
(13–15). In addition, activated factor X (factor Xa), coupled
with its cofactor Va, forming the prothrombinase complex on
phospholipid membranes, as well as the complex of tissue
factor and factor VIIa formed at the site of vascular injury that
activates factors IX and X, may exert persistent procoagulant
effects despite inhibition of preformed thrombin. Thus, either
higher doses of antithrombin agents or inhibition of prothrom-
bin activation may attenuate stenosis more optimally.
This study was designed to determine whether a brief
interval of profound inhibition of thrombin or inhibition of
activation of prothrombin mediated by factor Xa can attenuate
stenosis after balloon-induced injury of a carotid artery in
minipigs fed an atherogenic diet. We have recently character-
ized this preparation as one that rapidly evolves complex,
atherosclerotic-like lesions containing inﬁltrations of smooth
muscle cells, macrophages and organized thrombus, which are
prone to recurrent thrombosis and remodeling similar to
human atheroma (16).
Methods
Study protocol. Thirty male Yucatan minipigs (Charles
River Laboratories) weighing 20.4  3.3 kg were used. A
baseline blood sample was obtained for assay of serum choles-
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terol, and the animals were fed an atherogenic diet containing
4% cholesterol and 30% fat (Purina Test Diet #5748 M-A)
(16). After veriﬁcation that serum cholesterol levels had
exceeded 300 mg/dl (generally observed 2 weeks after initiating
the atherogenic diet), the pigs were sedated with intramuscular
ketamine (22 mg/kg), acepromazine (1.1 mg/kg) and atropine
(0.05 mg/kg). An ear vein was cannulated for administration of
ﬂuids and pentobarbital (20 mg/kg) to induce and maintain
anesthesia. An 8F catheter sheath was inserted aseptically into
an exposed femoral artery, and a bolus of heparin (200 U/kg)
was administered intravenously to prevent clot formation in
the catheters. The pigs were then randomly assigned to the
following intravenous anticoagulant regimens for 3 h at dos-
ages selected to increase the activated partial thromboplastin
time (aPTT) or prothrombin time (PT), or both, by four- to
six-fold: 1) additional heparin (100 U/kg per h); 2) recombi-
nant tick anticoagulant peptide (rTAP, 1 mg/kg as a bolus
followed by 3 mg/kg per h; Merck, Sharp, and Dohme, Inc.), a
speciﬁc inhibitor of factor Xa (17); or 3) recombinant desulfa-
tohirudin variant 1 (r-hirudin, 2 mg/kg as a bolus followed by
2 mg/kg per h; CGP 39393, Ciba-Geigy, Inc.). No antiplatelet
agents were administered.
Fifteen minutes after initiating the infusions of anticoagu-
lant agents, a baseline angiogram of the carotid arteries was
obtained and a balloon catheter (8 mm  2 cm, Proﬂex 5,
Mallinckrodt) was advanced into the left carotid artery to the
level of the second or third cervical vertebrae. The balloon was
inﬂated ﬁve times to a pressure of 8 atm for 30 s with 30 s
between inﬂations, which induces consistent rupture of the
internal elastic lamina and injury to the media (16,18). Patency
of the injured vessel was assessed immediately by angiography
and after 48 h by transcutaneous ultrasound (Hewlett-Packard,
Sonos 1500 scanner with a 7.5-MHz linear array transducer).
Blood samples were obtained from the arterial sheath for
analysis of aPTT and PT before the bolus of heparin, 15 min
after heparin (before the bolus of additional anticoagulant)
and hourly for 4 h after the administration of additional
heparin or other anticoagulant agents. After acquisition of the
4-h samples, the arterial sheath was removed, the femoral
artery was ligated and the incision was closed in layers. The
animals were recovered from anesthesia and were given am-
picillin (10 mg/kg intramuscularly) for 3 days after surgery.
One month after balloon-induced injury, patency of the
carotids was reassessed by angiography, and the arteries were
perfusion-ﬁxed in situ and excised for analysis of lumen
stenosis. All procedures involving animals were approved by
the Animal Studies Committee at our institution.
Coagulation assays. We measured PT and aPTT in cit-
rated plasma with the use of a Coag-A-Mate XM automated
coagulation timer (Organon Teknika).
Histologic analysis. The region of the injured carotid
artery with the smallest apparent lumen diameter was identi-
ﬁed angiographically and its location marked on the skin. Both
carotid arteries were perfused in situ with 300 ml of 0.9%
NaCl, followed by 500 ml of 4% paraformaldehyde delivered at
a constant pressure of 120 mm Hg through a 6F angiographic
catheter positioned proximally in the brachiocephalic artery. A
ligature was placed around the brachiocephalic artery contain-
ing the catheter to prevent retrograde ﬂow. The perfusion-
ﬁxed carotid arteries were excised, and 1-cm segments from
the site of stenosis identiﬁed angiographically and from the
same location in the contralateral, uninjured artery as a control
were placed in ﬁxative for 24 h. The segments were embedded
in parafﬁn and cut through their entirety at a thickness of 5 m,
and sets of sections collected every 100 m were stained with
hematoxylin-eosin, Masson’s trichrome stain for collagen,
Verhoeff–van Gieson stain for elastic tissue and Martius
scarlet blue stain to delineate ﬁbrin. Selected sections were
also immunostained with antibodies directed against alpha
actin (HHF35, Dako) to verify the presence of smooth muscle
cells.
The extent of lumen stenosis was measured in sections
exhibiting the smallest lumen diameters and stained for elastic
tissue (to enable identiﬁcation of the internal elastic lamina).
The microscopic images were digitized with the use of a Nikon
Optiphot-2 microscope with a CCD camera attached to a
Macintosh IIci computer outﬁtted with a NuVista frame-
grabber board. A reference dimensional scale was also digi-
tized to allow calibration of the image analysis software (Image
1.44, National Institutes of Health). The cross-sectional areas
of the lumen and neointima were planimetered by tracing the
margin of the lumen and internal elastic lamina. Percent lumen
obstruction was then calculated as 1, minus the area of the
lumen, divided by the area within the internal elastic lamina,
multiplied by 100.
Foam cell content in neointimal lesions was quantiﬁed by
counting the number of foam cells per high power ﬁeld (400)
in 25 randomly selected ﬁelds. The presence of thrombus was
deﬁned by the identiﬁcation of ﬁbrin within the lesion and was
graded as either present or absent.
Statistical analysis. Data are expressed as mean value 
SEM. Interval data such as changes in aPTT were compared
between groups by analysis of variance with a repeated mea-
sures design (Statview II, Abacus Concepts, Inc.). The un-
paired Student t test was used to compare the severity of lumen
stenosis between groups. A value of p  0.05 was considered
signiﬁcant.
Results
Of the 30 animals subjected to the carotid injury procedure,
two could not be used because of difﬁculties in achieving
adequate balloon hyperinﬂations. Three others died after the
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
PT  prothrombin time
r-hirudin  recombinant desulfatohirudin
rTAP  recombinant tick anticoagulant peptide
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procedure: one from shock induced by hypothermia, one from
an infection at the femoral cutdown site and another from
hemorrhage induced by a tracheal abrasion. None of the
remaining 25 animals that completed the protocol exhibited
occlusion of the injured carotid artery assessed ultrasonically
after 48 h. However, one animal from each of the treatment
groups exhibited complete vessel occlusion after 4 weeks.
These animals were excluded from further analysis because the
time of occlusion was unknown and occlusion, whenever it
occurred, would presumably alter the course of subsequent
neointimal formation. Two other animals were excluded be-
cause the extent of vascular injury was inadequate judging
from the absence of disruption of the internal elastic lamina.
Thus, results are those from 20 animals with sustained arterial
patency after marked vascular injury.
Serum cholesterol. Serum cholesterol increased markedly
after feeding the animals an atherogenic diet for 2 weeks, from
100  12 mg/dl at baseline to 650  163 mg/dl (p  0.05).
Cholesterol levels were unchanged 4 weeks after balloon-
induced arterial injury (603  145 mg/dl) and did not differ
between anticoagulant treatment groups.
Hematologic variables. Changes in plasma aPTT and PT
induced by brief administration of anticoagulant agents are
shown in Figure 1. Each of the anticoagulant regimens in-
creased the aPTT by six- to sevenfold. Prothrombin time was
increased three- to fourfold in animals given heparin or
r-hirudin but greater than fourfold in those given rTAP. The
maximal elevation of PT in rTAP-treated animals is an under-
estimate because a 50-s limit was used in its determination.
Hematologic variables had not yet returned to baseline levels
by the time of acquisition of the 4-h blood sample, although
aPTT in rTAP-treated and PT in r-hirudin–treated animals
were not signiﬁcantly different from baseline values. Despite
marked anticoagulation, spontaneous gingival bleeding did not
occur.
Lumen stenosis. Stenosis of the carotid artery lumen as-
sessed 4 weeks after balloon-induced injury is shown in Figure
2. Stenosis averaged 76% in heparin-treated animals and was
reduced somewhat in rTAP-treated animals. However, r-
hirudin–treated animals exhibited an average stenosis of 29%,
signiﬁcantly lower than values in animals given heparin.
Histologic analysis. Severe mural damage was evident in
all of the balloon-injured vessels by fragmentation of the
internal elastic lamina and by replacement of smooth muscle
cells in the media with collagen consistent with necrosis (Fig. 3
and 4). The pronounced neointimal lesions in heparin-treated
animals were characterized primarily by thrombus inﬁltrated
with foam cells and smooth muscle cells (Fig. 3, Table 1),
typical of lesions resulting from deep vascular injury in the
presence of sustained high levels of serum cholesterol, as we
have described previously (16). In contrast, animals given
r-hirudin exhibited a thin neointima comprised of smooth
muscle cells and foam cells but lacking appreciable thrombus
(Fig. 4, Table 1). Animals given rTAP exhibited neointimal
lesions more like those of heparin-treated animals, and in the
majority of animals the lesions contained thrombus (Table 1).
No intimal thickening or foam cells were observed in the
contralateral, uninjured carotid arteries in any treatment
group.
Figure 2. Effects of anticoagulant agents administered for 3 h after
balloon-induced injury to the carotid artery on percent stenosis of the
lumen assessed histologically 4 weeks later. *p  0.02 compared with
heparin-treated animals. TAP  tick anticoagulant peptide.
Figure 1. Effects of intravenous infusion of anticoagulant agents on
coagulation indexes measured serially in plasma. A, Activated partial
thromboplastin time (aPTT). B, Prothrombin time (PT).
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Discussion
Our results show that despite similar, marked anticoagula-
tion, direct inhibition of thrombin with r-hirudin appears to be
more effective than either direct inhibition of factor Xa with
rTAP or indirect inhibition of thrombin and factor Xa with
heparin for attenuation of stenosis after balloon-induced arte-
rial injury in minipigs (Fig. 2). Our results are also consistent
with results from previous studies in rabbits showing attenua-
tion of neointimal proliferation when r-hirudin either alone
(10) or in combination with D-Phe-Pro-Arg-chloromethyl ke-
tone (PPACK) (19), a synthetic irreversible inhibitor of throm-
bin, was administered for intervals of 2 h to 1 week after
arterial injury induced with a balloon catheter. In addition, our
results agree with results showing attenuation of neointimal
proliferation when r-hirudin was administered for up to 2
weeks after coronary stent angioplasty in minipigs (11). In
aggregate, these data support the hypothesis that thrombin is
an important mediator of neointimal formation and subse-
quent stenosis after vascular injury.
Mechanisms of neointimal formation involving thrombin.
Thrombin may contribute to the development of neointima
through several mechanisms. It converts ﬁbrinogen to ﬁbrin
and activates platelets, forming thrombus, which is a consistent
feature of neointima in patients who have had angioplasty
(20,21) and in animal preparations such as the one we used,
where deep injury to the vessel is induced, simulating plaque
rupture (16,22). Fibrin and factors released from platelets,
including platelet-derived growth factor, in turn, have been
shown to stimulate smooth muscle cell chemotaxis and prolif-
eration in vitro (23,24) and may contribute to the abundance of
these cells in neointimal lesions (25). Thrombin may stimulate
smooth muscle cell proliferation directly by binding to throm-
bin receptors that are upregulated after balloon-induced vas-
cular injury (7). Thrombin may also serve as a chemotactic
factor for inﬂammatory cells including macrophages (26).
Mechanisms for the efﬁcacy of r-hirudin. The mechanisms
by which r-hirudin reduced lesion development remain to be
determined, although inhibition of thrombin-induced throm-
bus formation at the site of vascular injury appears to be
involved (Table 1). Inhibition of cell proliferation may contrib-
ute as well, but a recent study has shown that r-hirudin infused
for 2 h after angioplasty failed to reduce 3H-thymidine incor-
poration into proliferating smooth muscle cells within 1 week
(27), suggesting that the effects on cell proliferation may be
minimal. Nonetheless, we administered twice as much
r-hirudin as these investigators did and twice the dosage that
others have shown to inhibit acute thrombus formation on
balloon-injured arteries (22). Thus, we cannot exclude the
possibility that the dosage of r-hirudin used directly inhibited
Figure 3. Photomicrograph of a representative carotid artery cross
section obtained from a pig that received heparin for 3 h after
balloon-induced injury. Cross sections were stained with Masson’s
trichrome stain for collagen. Balloon injury to the carotid artery was
extensive, as indicated by thinning and replacement of smooth muscle
cells in the media with lighter staining collagen (arrows). Neointima
almost completely ﬁlled the lumen (inset) and was composed of
organized thrombus (as deﬁned in other sections stained with Martius
scarlet blue for ﬁbrin), foam cells and smooth muscle cells (identiﬁed
in other sections stained for smooth muscle cell actin).
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thrombin action on smooth muscle cell proliferation in addi-
tion to its antithrombotic effect.
Interestingly, intravenous infusion of r-hirudin for only 3 h
ultimately reduced lumen stenosis after 1 month, despite
reports that thrombin activity is released from the exposed
subendothelium for up to 10 days after balloon denudation of
the aorta in rabbits (28). However, we have shown recently
(29) that negligible amounts of thrombin are actually bound to
the lumen surface of balloon-injured arteries, although the
potential to generate new thrombin persists for at least 24 h,
presumably because of the continued availability of tissue
factor and factor Xa associated with the lumen surface. In vivo
results showing prolonged inhibition of procoagulant activity
on clots and injured vessels after brief intravenous administra-
tion of r-hirudin (30) are consistent with it exhibiting a
protracted association with locally generated thrombin or with
an as yet undeﬁned component of thrombus or the vessel wall.
Effects of rTAP and heparin on lumen narrowing. Abun-
dant thrombus associated with the majority of lesions in
heparin- and rTAP-treated animals (Table 1) may explain why
these agents had little effect on stenosis. The results with
heparin are not unexpected because it accelerates the activity
of antithrombin III, which may not have been available in high
concentrations locally and is relatively ineffective for inhibiting
thrombin bound to ﬁbrin (31). The lack of signiﬁcant inhibition
of stenosis with rTAP was surprising because factor Xa is
essential for early thrombin elaboration after vascular injury
(29). However, our results are similar to those reported by
Ragosta et al. (32), who observed only a modest reduction in
lumen narrowing after 28 days in rabbits given rTAP for 2 h
after balloon angioplasty of focal femoral arterial lesions
induced previously by air desiccation injury and feeding cho-
lesterol. A more profound effect on lumen narrowing in this
preparation was observed with a longer acting inhibitor of
factor Xa, antistasin, suggesting that the reduced effectiveness
with rTAP may have resulted because it did not remain long
enough at the site of vascular injury. Effective local inhibition
of factor Xa with rTAP may have been limited also by a slow
kinetic rate of association (33). Whether our results reﬂect
inadequate inhibition of factor Xa as opposed to greater
efﬁcacy of direct inhibition of thrombin remains to be deter-
mined.
Figure 4. Photomicrograph of a representative carotid artery cross
section obtained from a pig that received r-hirudin for 3 h after
balloon-induced injury. Despite extensive vascular injury, as indicated
by the replacement of smooth muscle cells in the media with lighter
staining collagen (arrows), only a thin neointima lacking visible
thrombus was observed.
Table 1. Characteristics of Vascular Lesions
Treatment
Heparin
(n  6)
rTAP
(n  5)
r-Hirudin
(n  9)
Thrombus 80% 75% 22%*
Foam cells/HPF
(mean  SEM)
22  20 15  17 16  15
*p  0.01 compared with heparin- and rTAP-treated animals. HPF  high
power ﬁeld.
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Study limitation. The animal preparation we used, com-
bining deep vascular injury with a diet enriched with choles-
terol, has been shown to accelerate formation of plaque-like
lesions in pigs with characteristics of lipid, thrombus and
smooth muscle cells resembling more mature atherosclerotic
lesions from animals fed cholesterol alone for 1 to 2 years and
restenotic lesions in some patients (20,34,35). This preparation
is limited, however, because we have injured previously normal
vessels and have measured their stenosis rather than restenosis
after injury to preexisting atheromatous plaque analogous to
coronary angioplasty. Nevertheless, our results showing the
importance of thrombin in the vascular response to initial
balloon-induced injury should be relevant for repetitive inju-
ries as well.
Clinical implications. The pathophysiologic mechanisms
of both acute reocclusion and restenosis after coronary angio-
plasty appear to be related to thrombosis and its sequelae
(1,5). Morphologic studies in patients who died within 2 days
after angioplasty have revealed ruptured atheromatous
plaques coated with layers of platelets and ﬁbrin (35). Throm-
botic material has also been a consistent feature of atherec-
tomy specimens excised from restenotic lesions in living pa-
tients; with some thrombus at various stages of organization
evident in 65% to 75% of the specimens (21). Initial studies in
which modest intravenous doses of r-hirudin were adminis-
tered to patients undergoing coronary angioplasty showed a
decreased rate of early complications, but no difference in the
minimal lumen diameter at 7 months, compared with heparin-
treated control subjects (12). However, the results of our study
show that brief, more profound inhibition of thrombin with
r-hirudin attenuates thrombus and neointimal formation lead-
ing to stenosis after balloon-induced arterial injury in minipigs.
Although the intravenous dosage of r-hirudin that we used
resulted in marked prolongation of aPTT above a clinically
accepted range, high, local vascular concentrations of r-hirudin
are achieved with the use of catheter- or stent-based direct
delivery systems that may minimize systemic anticoagulation
(36). Accordingly, profound inhibition of thrombin achieved by
local delivery of antithrombin agents may warrant testing in
patients.
We thank Daud Ashai, MD, John Engelbach and Delbert McGraw for their
assistance with the animal preparations and Barbara Donnelly for preparation of
the manuscript.
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